Literature DB >> 28756110

A comparative meta-analysis of neurocognition in first-degree relatives of patients with schizophrenia and bipolar disorder.

E Bora1.   

Abstract

OBJECTIVE: Cognitive impairment is a familial and heritable aspect of major psychoses and might be a shared vulnerability marker for schizophrenia and BP. However, it is not clear whether some aspects of cognitive deficits are uniquely associated with risk for specific diagnoses.
METHODS: A novel meta-analysis of cognitive functions in first-degree relatives of probands with bipolar disorder (BP-Rel) and schizophrenia (Sch-Rel) was conducted. Current meta-analysis included 20 studies and compared cognitive functions of 1341 Sch-Rel, 939 BP-Rel and 1427 healthy controls.
RESULTS: Sch-Rel was associated with cognitive deficits in all domains (d=0.20-0.58) and BP-Rel underperformed healthy controls in processing speed, verbal fluency and speed based executive function tests (d=0.33-0.41). Sch-Rel underperformed BP-Rel in general intellectual ability, working memory, verbal memory, planning, processing speed and fluency (d=0.24-0.42).
CONCLUSIONS: Inefficiency in processing information and impaired processing speed might be common vulnerability factors for major psychoses. On the other hand, low performance in accuracy based tasks and deficits in general intellectual ability, verbal learning, planning and working memory might be more specifically associated with risk for schizophrenia.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Bipolar disorder; Cognition; Familial; Relatives; Schizophrenia

Mesh:

Year:  2017        PMID: 28756110     DOI: 10.1016/j.eurpsy.2017.06.003

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  7 in total

1.  Social Cognition, Language, and Social Behavior in 7-Year-Old Children at Familial High-Risk of Developing Schizophrenia or Bipolar Disorder: The Danish High Risk and Resilience Study VIA 7-A Population-Based Cohort Study.

Authors:  Camilla Jerlang Christiani; Jens R M Jepsen; Anne Thorup; Nicoline Hemager; Ditte Ellersgaard; Katrine S Spang; Birgitte K Burton; Maja Gregersen; Anne Søndergaard; Aja N Greve; Ditte L Gantriis; Gry Poulsen; Md Jamal Uddin; Larry J Seidman; Ole Mors; Kerstin J Plessen; Merete Nordentoft
Journal:  Schizophr Bull       Date:  2019-10-24       Impact factor: 9.306

Review 2.  Neurocognitive functioning in bipolar disorder: What we know and what we don't.

Authors:  Kamyar Keramatian; Ivan J Torres; Lakshmi N Yatham
Journal:  Dialogues Clin Neurosci       Date:  2022-06-01

3.  Heterogeneity of social cognitive and language functions in children at familial high-risk of severe mental illness; The Danish High Risk and Resilience Study VIA 7.

Authors:  Merete Nordentoft; Jens Richardt Møllegaard Jepsen; Camilla Jerlang Christiani; Nicoline Hemager; Ditte Ellersgaard; Anne A E Thorup; Katrine Søborg Spang; Birgitte Klee Burton; Maja Gregersen; Anne Søndergaard; Aja Greve; Ditte Lou Gantriis; Ole Mors; Kerstin J Plessen
Journal:  Eur Child Adolesc Psychiatry       Date:  2021-02-09       Impact factor: 4.785

4. 

Authors:  Sara Sorella; Gaia Lapomarda; Irene Messina; Jon Julius Frederickson; Roma Siugzdaite; Remo Job; Alessandro Grecucci
Journal:  Neuroimage Clin       Date:  2019-05-04       Impact factor: 4.881

Review 5.  Cognitive dysfunction in schizophrenia: An expert group paper on the current state of the art.

Authors:  Philip D Harvey; Marta Bosia; Roberto Cavallaro; Oliver D Howes; René S Kahn; Stefan Leucht; Daniel R Müller; Rafael Penadés; Antonio Vita
Journal:  Schizophr Res Cogn       Date:  2022-03-22

6.  Does Cognitive Dysfunction in Bipolar Disorder Qualify as a Diagnostic Intermediate Phenotype?-A Perspective Paper.

Authors:  Lars Vedel Kessing; Kamilla Miskowiak
Journal:  Front Psychiatry       Date:  2018-10-08       Impact factor: 4.157

Review 7.  Evaluating endophenotypes for bipolar disorder.

Authors:  Riccardo Guglielmo; Kamilla Woznica Miskowiak; Gregor Hasler
Journal:  Int J Bipolar Disord       Date:  2021-05-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.